|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | 高血压患者脑小血管病变化对认知功能的影响显示文摘高血压是脑小血管病进展与认知功能障碍的主要危险因素之一。该研究旨在探讨高血压患者脑小血管病损伤变化与认知功能减退及轻度认知功能障碍的关系。该研究的数据从ISSYS队列(探讨高血压无症状性脑卒中:一个磁共振成像研究)中获得,其是一项纵向人群研究,纳入基线无痴呆及脑卒中,年龄50~70岁的高血压患者。 | Jiménez-Balado J Riba-Llena I Abril O Garde E Penalba A Ostos E Maisterra O Montaner J Noviembre M Mundet X Ventura O Pizarro J Delgado P 赵狄 练桂丽 | 2019 | 中华高血压杂志2019，27，2： | 15 |
| 2 | Metabolic complications in liver transplant recipients显示文摘The metabolic syndrome(MS), which includes obesity,dyslipidaemia, hypertension and hyperglycaemia according to the most widely accepted definitions now used, is one of the most common post-transplant complications, with a prevalence of 44%-58%. The MS, together with the immunosuppression, is considered the main risk factor for the development of cardiovascular disease(CVD) in transplant recipients, which in turn accounts for 19%-42% of all deaths unrelated to the graft. The presence of MS represents a relative risk for the development of CVD and death of 1.78. On the other hand, non-alcoholic fatty liver disease(NAFLD), considered as the manifestation of the MS in the liver, is now the second leading reason for liver transplantation in the United States after hepatitis C and alcohol. NAFLD has a high rate of recurrence in the liver graft and a direct relation with the worsening of other metabolic disorders, such as insulin resistance or diabetes mellitus. Consequently, it is vitally important to identify and treat as soon as possible such modifiable factors as hypertension, overweight, hyperlipidaemia or diabetes in transplanted patients to thus minimise the impact on patient survival. Additionally, steroid-free regimens are favoured, with minimal immunosuppression to limit the possible effects on the development of the MS. | Miguel Jiménez-Pérez Rocío González-Grande Edith Omonte Guzmán Víctor Amo Trillo Juan Miguel Rodrigo López | 2016 | World Journal of Gastroenterology2016，22，28： | 10 |
| 3 | New approaches in the treatment of hepatitis C显示文摘About 130-170 million people, is estimated to be infected with the hepatitis C virus(HCV). Chronic HCV infection is one of the leading causes of liverrelated death and in many countries it is the primaryreason for having a liver transplant. The main aim of antiviral treatment is to eradicate the virus. Until a few years ago the only treatment strategy was based on the combination of pegylated interferon and ribavirin(PEG/RBV). However, in genotypes 1 and 4 the rates of viral response did not surpass 50%, reaching up to 80% in the rest. In 2011 approval was given for the first direct acting antiviral agents(DAA), boceprevir and telaprevir, for treatment of genotype 1, in combination with traditional dual therapy. This strategy managed to increase the rates of sustained viral response(SVR) in both naive patients and in retreated patients, but with greater toxicity, interactions and cost, as well as being less safe in patients with advanced disease, in whom this treatment can trigger decompensation or even death. The recent, accelerated incorporation since 2013 of new more effective DAA, with pan-genomic properties and excellent tolerance, besides increasing the rates of SVR(even up to 100%), has also created a new scenario: shorter therapies, less toxicity and regimens free of PEG/RBV. This has enabled their almost generalised applicability in all patients. However, it should be noted that most of the scientific evidence available is based on expert opinion, case-control series, cohort studies and phase 2 and 3 trials, some with a reduced number of patients and select groups. Few data are currently available about the use of these drugs in daily clinical practice, particularly in relation to the appearance of side effects and interactions with other drugs, or their use in special populations or persons with the less common genotypes. This situation suggests the need for the generalised implementation of registries of patients receiving antiviral therapy. The main inconvenience of these new drugs is their high cost. This necessitates selection and prioritization of candidate patients to receive them, via strategies established by the various national organs, in accordance with the recommendations of scientific societies. | rocío gonzález-grande miguel jiménez-pérez carolina gonzález arjona josémostazo torres | 2016 | World Journal of Gastroenterology2016，22，4： | 9 |
| 4 | 猪的回肠炎及其控制显示文摘 | Jim O Donovan 余春明 | 2002 | 中国畜牧兽医2002，29，4： | 4 |
| 5 | Management of recurrent hepatitis C virus after liver transplantation显示文摘Chronic hepatitis C virus(HCV) infection is the leading cause of death from liver disease and the leading indication for liver transplantation(LT) in the United States and western Europe. LT represents the best therapeutic alternative for patients with advanced chronic liver disease caused by HCV or those who develop hepatocarcinoma. Reinfection by HCV of the graft is universal and occurs in 95% of transplant patients. This reinfection can compromise graft function and patient survival. In a few cases, the histological recurrence is minimal and non-progressive; however, in most patients it follows a more rapid course than in immunocompetent persons, and frequently evolves into cirrhosis with graft loss. In fact, the five-year and ten-year survival of patients transplanted because of HCV are 75% and 68%, respectively, compared with 85% and 78% in patients transplanted for other reasons. There is also a pattern of recurrence that is very severe, but rare(< 10%), called fibrosing cholestatic hepatitis, which often involves rapid graft loss. Patients who present a negative HCV viremia after antiviral treatment have better survival. Many studies published over recent years have shown that antiviral treatment of post-transplant HCV hepatitis carried out during the late phase is the best option for improving the prognosis of these patients. Until 2011, PEGylated interferon plus ribavirin was the standard of care, resulting in a sustained virological response in around 30% of recipients. The addition of protease inhibitors, such as boceprevir or telaprevir, to the standard of care, or the use of other direct-acting antiviral drugs may involve therapeutic changes in the context of HCV recurrence. This may result a better prognosis for these patients, particularly those with severe recurrence or factors predicting rapid progression of fibrosis. However, the use of these agents in LT still requires clarification in terms of safety and efficacy. | Miguel Jiménez-Pérez Rocío González-Grande Francisco Javier Rando-Mu?oz | 2014 | World Journal of Gastroenterology2014，20，44： | 3 |
| 6 | Management of hepatitis B virus infection after liver transplantation显示文摘Chronic hepatitis B virus(HBV) infection is responsible for up to 30% of cases of liver cirrhosis and up to 53% of cases of hepatocellular carcinoma. Liver transplantation(LT) is the best therapeutic option for patients with end-stage liver failure caused by HBV. The success of transplantation, though, depends on receiving prophylactic treatment against post-transplant viral reactivation. In the absence of prophylaxis, liver transplantation due to chronic hepatitis B(CHB) is associated with high rates of viral recurrence and poor survival. The introduction of treatment with hepatitis B immunoglobulins(HBIG) during the 1990 s and later the incorporation of oral antiviral drugs have improved the prognosis of these patients. Thus, LT for CHB is now a universally accepted option, with an estimated 5 years survival of around 85% vs the 45% survival seen prior to the introduction of HBIG. The combination of lamivudine plus HBIG has for many years been the most widely used prophylactic regimen. However, with the appearance of new more potent oral antiviral agents associated with less resistance(e.g., entecavir and tenofovir) for the treatment of CHB, new prophylactic strategies are being designed, either in combination with HBIG or alone as a monotherapy. These advances have allowed for more personalized prophylaxis based on the individual risk profile of a given patient. In addition, the small pool of donors has required the use of anti-HBc-positive donors(with the resulting possibility of transmitting HBV from these organs), which has been made possible by suitable prophylactic regimens. | Miguel Jiménez-Pérez Rocío González-Grande José Mostazo Torres Carolina González Arjona Francisco Javier Rando-Mu?oz | 2015 | World Journal of Gastroenterology2015，21，42： | 3 |
| 7 | A framework infrageneric classification of Carex (Cyperaceae) and its organizing principles显示文摘Phylogenetic studies of Carex L.(Cyperaceae)have consistently demonstrated that most subgenera and sections are para-or polyphyletic.Yet,taxonomists continue to use subgenera and sections in Carex classification.Why?The Global Carex Group(GCG)here takes the position that the historical and continued use of subgenera and sections serves to(i)organize our understanding of lineages in Carex,(ii)create an identification mechanism to break the~2000 species of Carex into manageable groups and stimulate its study,and(iii)provide a framework to recognize morphologically diagnosable lineages within Carex.Unfortunately,the current understanding of phylogenetic relationships in Carex is not yet sufficient for a global reclassification of the genus within a Linnean infrageneric(sectional)framework.Rather than leaving Carex classification in its current state,which is misleading and confusing,we here take the intermediate steps of implementing the recently revised subgeneric classification and using a combination of informally named clades and formally named sections to reflect the current state of our knowledge.This hybrid classification framework is presented in an order corresponding to a linear arrangement of the clades on a ladderized phylogeny,largely based on the recent phylogenies published by the GCG.It organizes Carex into six subgenera,which are,in turn,subdivided into 62 formally named Linnean sections plus 49 informal groups.This framework will serve as a roadmap for research on Carex phylogeny,enabling further development of a complete reclassification by presenting relevant morphological and geographical information on clades where possible and standardizing the use of formal sectional names. | Eric H.Roalson Pedro Jiménez-Mejías Andrew L.Hipp Carmen Benítez-Benítez Leo P.Bruederle Kyong-Sook Chung Marcial Escudero Bruce A.Ford Kerry Ford Sebastian Gebauer Berit Gehrke Marlene Hahn Muhammad Qasim Hayat Mathias H.Hoffmann Xiao-Feng Jin Sangtae Kim Isabel Larridon Étienne Léveillé-Bourret Yi-Fei Lu Modesto Luceño Enrique Maguilla Jose IgnacioMárquez-Corro Santiago Martín-Bravo Tomomi Masaki Mónica Míguez Robert F.C.Naczi Anton A.Reznicek Daniel Spalink Julian R.Starr Uzma Tamara Villaverde Marcia J.Waterway Karen L.Wilson and Shu-Ren Zhang | 2021 | Journal of Systematics and Evolution2021，59，4： | 3 |
| 8 | ARFI, FibroScan?, ELF, and their combinations in the assessment of liver fibrosis: A prospective study显示文摘 | Gonzalo Crespo Guillermo Fernández-Varo Zoe Mari?o Gregori Casals Rosa Miquel Stella M. Martínez Rosa Gilabert Xavier Forns Wladimiro Jiménez Miquel Navasa | 2012 | Journal of Hepatology2012，，2： | 3 |
| 9 | Treatment of chronic hepatitis C with direct-acting antivirals: The role of resistance显示文摘The use of direct-acting antivirals(DAAs) to treat chronic hepatitis C has resulted in a significant increase in rates of sustained viral response(around 90%-95%) as compared with the standard treatment of peginterferon/ribavirin. Despite this, however, the rates of therapeutic failure in daily clinical practice range from 10%-15%. Most of these cases are due to the presence of resistant viral variants, resulting from mutations produced by substitutions of amino acids in the viral target protein that reduce viral sensitivity to DAAs, thus limiting the efficacy of these drugs. The high genetic diversity of hepatitis C virus has resulted in the existence of resistance-associated variants(RAVs), sometimes even before starting treatment with DAAs, though generally at low levels. These preexisting RAVs do not appear to impact on the sustained viral response, whereas those that appear after DAA therapy could well be determinant in virological failure with future treatments. As well as the presence of RAVs, virological failure to treatment with DAAs is generally associated with other factors related with a poor response, such as the degree of fibrosis, the response to previous therapy, the viral load or the viral genotype. Nonetheless, viral breakthrough and relapse can still occur in the absence of detectable RAVs and after the use of highly effective DAAs, so that the true clinical impact of the presence of RAVs in therapeutic failure remains to be determined. | Miguel Jiménez-Pérez Rocío González-Grande Pilar Espana Contreras Isabel Pinazo Martínez Jesús de la Cruz Lombardo Raúl Olmedo Martín | 2016 | World Journal of Gastroenterology2016，22，29： | 3 |
| 10 | Dendritic cell deficiencies persist seven months after SARS-CoV-2 infection显示文摘Severe Acute Respiratory Syndrome Coronavirus(SARS-CoV)-2 infection induces an exacerbated inflammation driven by innate immunity components.Dendritic cells(DCs)play a key role in the defense against viral infections,for instance plasmacytoid DCs(pDCs),have the capacity to produce vast amounts of interferon-alpha(IFN-α).In COVID-19 there is a deficit in DC numbers and IFN-αproduction,which has been associated with disease severity.In this work,we described that in addition to the DC deficiency,several DC activation and homing markers were altered in acute COVID-19 patients,which were associated with multiple inflammatory markers.Remarkably,previously hospitalized and nonhospitalized patients remained with decreased numbers of CD1c+myeloid DCs and pDCs seven months after SARS-CoV-2 infection.Moreover,the expression of DC markers such as CD86 and CD4 were only restored in previously nonhospitalized patients,while no restoration of integrinβ7 and indoleamine 2,3-dyoxigenase(IDO)levels were observed.These findings contribute to a better understanding of the immunological sequelae of COVID-19. | Alberto Pérez-Gómez Joana Vitallé Carmen Gasca-Capote Alicia Gutierrez-Valencia María Trujillo-Rodriguez Ana Serna-Gallego Esperanza Muñoz-Muela María de los Reyes Jiménez-Leon Mohamed Rafii-El-Idrissi Benhnia Inmaculada Rivas-Jeremias Cesar Sotomayor Cristina Roca-Oporto Nuria Espinosa Carmen Infante-Domínguez Juan Carlos Crespo-Rivas Alberto Fernández-Villar Alexandre Pérez-González Luis Fernando López-Cortés Eva Poveda Ezequiel Ruiz-Mateos JoséMiguel Cisneros Sonsoles Salto-Alejandre Judith Berastegui-Cabrera Pedro Camacho-Martínez Carmen Infante-Domínguez Marta Carretero-Ledesma Juan Carlos Crespo-Rivas Eduardo Márquez JoséManuel Lomas Claudio Bueno Rosario Amaya JoséAntonio Lepe Jerónimo Pachón Elisa Cordero Javier Sánchez-Céspedes Manuela Aguilar-Guisado Almudena Aguilera Clara Aguilera Teresa Aldabo-Pallas Verónica Alfaro-Lara Cristina Amodeo Javier Ampuero María Dolores Avilés Maribel Asensio Bosco Barón-Franco Lydia Barrera-Pulido Rafael Bellido-Alba Máximo Bernabeu-Wittel Candela Caballero-Eraso Macarena Cabrera Enrique Calderón Jesús Carbajal-Guerrero Manuela Cid-Cumplido Yael Corcia-Palomo Juan Delgado Antonio Domínguez-Petit Alejandro Deniz Reginal Dusseck-Brutus Ana Escoresca-Ortega Fátima Espinosa Nuria Espinosa Michelle Espinoza Carmen Ferrándiz-Millón Marta Ferrer Teresa Ferrer Ignacio Gallego-Texeira Rosa Gámez-Mancera Emilio García Horacio García-Delgado Manuel García-Gutiérrez María Luisa Gascón-Castillo Aurora González-Estrada Demetrio González Carmen Gómez-González Rocío González-León Carmen Grande-Cabrerizo Sonia Gutiérrez Carlos Hernández-Quiles Inmaculada Concepción Herrera-Melero Marta Herrero-Romero Luis Jara Carlos Jiménez-Juan Silvia Jiménez-Jorge Mercedes Jiménez-Sánchez Julia Lanseros-Tenllado Carmina López Isabel López Álvaro López-Barrios Luis F.López-Cortés Rafael Luque-Márquez Daniel Macías-García Guillermo Martín-Gutiérrez Luis Martín-Villén JoséMolina Aurora Morillo María Dolores Navarro-Amuedo Dolores Nieto-Martín Francisco Ortega María Paniagua-García Amelia Peña-Rodríguez Esther Pérez Manuel Poyato Julia Praena-Segovia Rafaela Ríos Cristina Roca-Oporto Jesús F.Rodríguez María Jesús Rodríguez-Hernández Santiago Rodríguez-Suárez Ángel Rodríguez-Villodres Nieves Romero-Rodríguez Ricardo Ruiz Zida Ruiz de Azua Celia Salamanca Sonia Sánchez Víctor Manuel Sánchez-Montagut César Sotomayor Alejandro Suárez Benjumea Javier Toral | 2021 | Cellular & Molecular Immunology2021，18，9： | 2 |
| 11 | FUSARIUM-ID v. 1.0: A DNA Sequence Database for Identifying Fusarium显示文摘 | David M. Geiser María del Mar Jiménez-Gasco Seogchan Kang Izabela Makalowska Narayanan Veeraraghavan Todd J. Ward Ning Zhang Gretchen A. Kuldau Kerry O’donnell | 2004 | European Journal of Plant Pathology (-)2004，，5： | 2 |
| 12 | 更完善的G20和全新的G7+:新世纪的需要显示文摘2008年金融危机期间,G20集团匆匆升级为'全球经济指导委员会'。在危机初期,G20集团是个有效遏制危机的组织。随着危机的减缓,G20集团既迷失了方向也失去了动力。各国政要认为没有必要再全力一致行动,转而关注各自的国内要务,他们认为这才是他们的职责所在。其实,有效的全球管理是长期的需要,并不仅限于危机期间。我们需要一种更具代表性、更有效的全球管理机制来预防危机,而不仅仅是对危机作出反应。 | Jim O'Neill Alessio Terzi 岳韦 张薇 | 2015 | 世界经济研究2015，，4： | 2 |
| 13 | Data-driven brain MRI segmentation supported on edge confidence and a priori tissue information显示文摘 | Jiménez-Alaniz J R Medina-Banuelos V Yánez-Suárez O | 2006 | IEEE Trans on Medical Imaging2006，25，1： | 1 |
| 14 | Glycosylation of individual whey proteins by Maillard reaction using dextran of different molecular mass显示文摘 | Laura Jiménez-Casta?o Mar Villamiel Rosina López- Fandi?o | 2007 | Food Hydrocolloids2007，21，3： | 1 |
| 15 | The banana(Musa acuminata)genome andthe evolution of monocotyledonous plants显示文摘 | HONT A D DENOEUD F AURY J M BAURENSF C CARREELF GARSMEUR O NOEL B BOCS S DROC G ROUARD M SILVA C D JABBARI K CARDI C POULAIN J SOUQUET M LABADIEK JOURDA C LENGELLE J MARGUERITE R G ALBERTI A BERNARD M CORREA M AYYAMPALAYAM S MCKAIN M R JIM L M | 2012 | Nature2012，488，： | 1 |
| 16 | A randomised controlled trial of intervention site radiotherapy in malignant pleural mesothelioma显示文摘 | Noelle O Rourke Jose Curto Garcia Jim Paul | 2007 | Radiotherapy and Oncology2007，84，： | 1 |
| 17 | MicroRNA expression profiling in Imatinib-resistant chronic myeloid leukemia patients without clinically significant ABL1-mutations显示文摘 | SAN JOS(E) EN(E)RIZ E ROM(A)N G(O)MEZ J JIM(E)NEZ VELASCO A | | 0，，： | 1 |
| 18 | Evaluating research efficiency within National R&D Programmes显示文摘 | Fernando Jiménez-Sáez Jon Mikel Zabala-Iturriagagoitia José L. Zofío Elena Castro-Martínez | 2010 | Research Policy2010，，2： | 1 |
| 19 | Phage therapy in the food industry 显示文摘 | Lorraine Endersen Jim O'Mahony Colin Hill | 2014 | Annu Rev Food Sci Technol2014，5，： | 1 |
| 20 | Determination of quinolones in chicken tissues by liquid chromatography with ultraviolet absorbance detection显示文摘 | Bailac S Ballesteros O Jiménez-Lozano E | | 0，，： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员